Press releases

June 19, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

June 03, 2026

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

Read more

May 22, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

May 06, 2026

Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

Read more

May 05, 2026

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

Read more

April 29, 2026

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

Read more

April 24, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

April 02, 2026

Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Read more

March 30, 2026

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

Read more

March 20, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more